Diversified Consumer Services
Company Overview of The Hong Kong Polytechnic University
The Hong Kong Polytechnic University is an educational institution.
Li Ka Shing Tower
Key Executives for The Hong Kong Polytechnic University
The Hong Kong Polytechnic University does not have any Key Executives recorded.
The Hong Kong Polytechnic University Key Developments
The Hong Kong Polytechnic University Presents at Macquarie Global Quantative Research Conference, Jul-23-2015 08:40 AM
Jul 20 15
The Hong Kong Polytechnic University Presents at Macquarie Global Quantative Research Conference, Jul-23-2015 08:40 AM. Venue: Hong Kong. Speakers: James Ohlson, Professor.
The Hong Kong Polytechnic University Presents at 11th China Hotel Investment Conference (CHIC), May-12-2015
May 9 15
The Hong Kong Polytechnic University Presents at 11th China Hotel Investment Conference (CHIC), May-12-2015 . Venue: Mandarin Oriental Pudong, Shanghai, China. Speakers: Xiao Qu, Program Leader, Hotel and Tourism Management (China) Program.
Kinex Pharmaceuticals Licenses Patents from Hong Kong Polytechnic University and McGill University
Feb 13 15
Kinex Pharmaceuticals announced the exclusive licensing of global rights of three patents from The Hong Kong Polytechnic University and McGill University. These three patents covered the inventions by Professor Larry Chow and Professor William Chan including novel new chemical compounds that have nanomolar potency against a molecular target named Breast Cancer Resistance Protein (BCRP). BCRP is a protein pump known to pump drugs, including anticancer drugs, from cancer cells that can lead to drug resistance; and also to pump drugs back into gastrointestinal tract, which prevent some useful drugs to be delivered to their target. The development of this technology, if successful, will expand the current Kinex oral drug absorption development platform. That platform currently includes the inhibition of P-glycoprotein that Kinex licensed from Hanmi in 2011. The lead molecule, HM30181A, has been shown in clinical studies to enhance the absorption of anticancer drugs including paclitaxel and irinotecan into orally available drugs. The lead program, Oraxol (an oral form of paclitaxel), has demonstrated clinical efficacy and an excellent safety profile in patient studies. Kinex is also actively developing other proprietary oral drug delivery platforms. The addition of another oral absorption delivery technology platform will further strengthen Kinex's arsenal of converting greater classes of intravenous drugs into oral versions. The terms of this exclusive license include upfront payments, milestones and royalties. Kinex is also committing to support research programs in Professor Larry Chow's laboratory to further develop this platform collaboratively with Kinex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries